Who
Steve Harr
President & CEO
Company insider
Files Form 4 as: President & CEO, Sana Biotechnology; Director, Loxo Oncology; CFO & Head, Corp. Development, Juno Therapeutics.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $5.2M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 3 Mar 2015
- Last trade
- 9 Mar 2026
- Last filed
- 10 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code F | $36K11,526 at $3.13 | filing |
| 9 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code F | $40K12,819 at $3.10 | filing |
| 9 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code F | $36K11,526 at $3.13 | filing |
| 9 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code F | $40K12,819 at $3.10 | filing |
| 7 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 7 Mar 2026filed 10 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 7 Mar 2026filed 10 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 7 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code M | —41,666 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —41,666 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —41,666 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code M | —41,666 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 10 Mar 2025filed 10 Mar 2025 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code F | $33K12,820 at $2.56 | filing |
| 7 Mar 2025filed 10 Mar 2025 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 7 Mar 2025filed 10 Mar 2025 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —166,667 at $0.00 | filing |
News
Netflix Stranger Things' New Episodes Are Officially The End Of An Era For Steve Harringtonscreenrant.com · 18 Sep 2026
1 headline in the last 90 days name Steve Harr; no company of theirs resolves to a name we track.